Description
Retina Health Market Forecast till 2030
Market Overview
During the forecast period, the retina health market is anticipated to grow at a CAGR of 7.01%. The term “retina” refers to the thin layer located at the back of the eye that transforms light entering the eye into electrical signals that the brain may process into images. The prevention of vision problems and even blindness depends on a healthy retina.
The increasing frequency of retinal disorders worldwide and the increase in strategic initiatives are credited with driving the growth of the global market for retinal health. In addition, more public and private groups are taking action to raise awareness of retinal illnesses. However, it is projected that the dearth of knowledge about retinal illnesses may impede market expansion.
The global retina health market is expected to witness a substantial market expansion due to the increasing incidences of retinal illnesses like retinitis pigmentosa, diabetic retinopathy, Age-Related Macular Degeneration (AMD), and retinal detachment. Additionally, the market has grown because of the rising prevalence of myopia and cases of vision impairment, particularly during the COVID-19 epidemic.
This is because more people are using screens and participating in virtual meetings while working from home, which has increased the prevalence of myopia and raised the chance of developing other progressive eye diseases including AMD. Additionally, growing consumer knowledge of retinal biologics fuels market expansion.
Market Segmentation
Based on the treatment and disease indication, the global market for retinal health has been segmented. The market is divided into categories for medications, therapy, and surgery based on the type of treatment. The global retina health market has been divided into age-related macular degeneration, diabetic retinopathy, inherited retinal illnesses, retinoblastoma, and others based on the indication of the disease.
Regional Analysis
Because of the high prevalence of retinal illnesses and the presence of significant market participants in the region, the North American retina health market is expanding.
Due to reasons like the high prevalence of wet AMD, rising diabetes rates, and many elderly individuals, the European retina health market is expanding.
Due to the rapidly developing healthcare infrastructure, rising per capita income, rising public awareness of eye health, and the presence of a sizable senior population, the Asia-Pacific (APAC) retina health market is anticipated to register a robust CAGR of 8.33% from 2022 to 2030.
The Middle East, Africa, and Latin America are the remainder of the world. Due to its weak economy, inadequate healthcare infrastructure, lack of qualified experts, and low level of public awareness, the remainder of the globe is predicted to have a slower CAGR than other regions.
Major Players
The key players operating in the global retina health market include Gensight Biologics (France), Novartis AG (Switzerland), Spark Therapeutics, Inc. (Us), Allergan Plc (Subsidiary of AbbVie Inc.) (Ireland), Hemera Biosciences LLC (US), Santen Pharmaceuticals Inc. (Japan), Regenxbio Inc. (US), Oxford Biomedica Plc (UK), Meiragtx Limited (US), Applied Genetic Technologies Corporation (AGTC) (US).
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 OVERVIEW
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 GROWING PREVALENCE OF RETINAL DISEASES ACROSS THE GLOBE
4.2.2 RISING NUMBER OF STRATEGIC INITIATIVES
4.3 RESTRAINTS
4.3.1 LACK OF AWARENESS REGARDING RETINAL DISEASES
4.4 OPPORTUNITY
4.4.1 INCREASING INITIATIVES BY PUBLIC AND PRIVATE ORGANIZATIONS TO DRIVE AWARENESS REGARDING RETINAL DISEASES
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION & SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER’S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE RETINA HEALTH MARKET
5.3.1 IMPACT ON SUPPLY CHAIN
5.3.2 IMPACT ON PRODUCTION
5.3.3 IMPACT ON MARKET PLAYERS
5.3.4 IMPACT ON DEMAND
6 GLOBAL RETINA HEALTH MARKET, BY TREATMENT
6.1 OVERVIEW
6.2 DRUGS
6.3 THERAPY
6.3.1 GENE THERAPY
6.3.2 NUTRITION THERAPY
6.3.3 OTHERS
6.4 SURGERY
7 GLOBAL RETINA HEALTH MARKET, BY DISEASE INDICATION
7.1 OVERVIEW
7.2 AGE-RELATED MACULAR DEGENERATION
7.3 DIABETIC RETINOPATHY
7.4 INHERITED RETINAL DISEASES
7.5 RETINOBLASTOMA
7.6 OTHERS
8 GLOBAL RETINA HEALTH MARKET, BY REGION
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 US
8.2.2 CANADA
8.3 EUROPE
8.3.1 GERMANY
8.3.2 UK
8.3.3 FRANCE
8.3.4 ITALY
8.3.5 SPAIN
8.3.6 REST OF EUROPE
8.4 ASIA-PACIFIC
8.4.1 JAPAN
8.4.2 CHINA
8.4.3 INDIA
8.4.4 AUSTRALIA
8.4.5 SOUTH KOREA
8.4.6 REST OF ASIA-PACIFIC
8.5 REST OF THE WORLD
8.5.1 MIDDLE EAST
8.5.2 AFRICA
8.5.3 LATIN AMERICA
9 COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPETITIVE BENCHMARKING
9.3 MAJOR GROWTH STRATEGY IN THE GLOBAL RETINA HEALTH MARKET
9.4 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL RETINA HEALTH MARKET
9.5 KEY DEVELOPMENT ANALYSIS
9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
9.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL
9.6.2 MERGER & ACQUISITIONS
9.6.3 EXPANSION
9.6.4 AGREEMENT/MARKETING STRATEGIES
9.7 FINANCIAL MATRIX
9.7.1 SALES (USD MILLION), 2021
9.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2021
10 COMPANY PROFILES
10.1 NOVARTIS AG
10.1.1 COMPANY OVERVIEW
10.1.2 FINANCIAL OVERVIEW
10.1.3 PRODUCTS/SERVICES OFFERED
10.1.4 KEY DEVELOPMENTS
10.1.5 SWOT ANALYSIS
10.1.6 KEY STRATEGIES
10.2 SPARK THERAPEUTICS, INC.
10.2.1 COMPANY OVERVIEW
10.2.2 FINANCIAL OVERVIEW
10.2.3 PRODUCTS/SERVICES OFFERED
10.2.4 KEY DEVELOPMENTS
10.2.5 KEY STRATEGIES
10.3 GENSIGHT BIOLOGICS
10.3.1 COMPANY OVERVIEW
10.3.2 FINANCIAL OVERVIEW
10.3.3 PRODUCTS/SERVICES OFFERED
10.3.4 KEY DEVELOPMENTS
10.3.5 KEY STRATEGIES
10.4 ALLERGAN PLC (SUBSIDIARY OF ABBVIE INC.)
10.4.1 COMPANY OVERVIEW
10.4.2 FINANCIAL OVERVIEW
10.4.3 PRODUCTS/SERVICES OFFERED
10.4.4 KEY DEVELOPMENTS
10.4.5 SWOT ANALYSIS
10.4.6 KEY STRATEGIES
10.5 OXFORD BIOMEDICA PLC
10.5.1 COMPANY OVERVIEW
10.5.2 FINANCIAL OVERVIEW
10.5.3 PRODUCTS/SERVICES OFFERED
10.5.4 KEY DEVELOPMENTS
10.5.5 KEY STRATEGIES
10.6 HEMERA BIOSCIENCES LLC
10.6.1 COMPANY OVERVIEW
10.6.2 FINANCIAL OVERVIEW
10.6.3 PRODUCTS/SERVICES OFFERED
10.6.4 KEY DEVELOPMENTS
10.6.5 SWOT ANALYSIS
10.6.6 KEY STRATEGIES
10.7 SANTEN PHARMACEUTICALS INC.
10.7.1 COMPANY OVERVIEW
10.7.2 FINANCIAL OVERVIEW
10.7.3 PRODUCTS OFFERED
10.7.4 KEY DEVELOPMENTS
10.7.5 SWOT ANALYSIS
10.7.6 KEY STRATEGIES
10.8 REGENXBIO INC.
10.8.1 COMPANY OVERVIEW
10.8.2 FINANCIAL OVERVIEW
10.8.3 PRODUCTS OFFERED
10.8.4 KEY DEVELOPMENTS
10.8.5 SWOT ANALYSIS
10.8.6 KEY STRATEGIES
10.9 MEIRAGTX LIMITED
10.9.1 COMPANY OVERVIEW
10.9.2 FINANCIAL OVERVIEW
10.9.3 PRODUCTS OFFERED
10.9.4 KEY DEVELOPMENTS
10.9.5 KEY STRATEGIES
10.10 APPLIED GENETIC TECHNOLOGIES CORPORATION (AGTC)
10.10.1 COMPANY OVERVIEW
10.10.2 FINANCIAL OVERVIEW
10.10.3 PRODUCTS OFFERED
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIES
11 APPENDIX
11.1 REFERENCES
11.2 RELATED REPORTS
Reviews
There are no reviews yet.